Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
6357- DRE,    New Perspectives on the Effect of Dandelion, Its Food Products and Other Preparations on the Cardiovascular System and Its Diseases
- Review, Nor, NA
*cardioP↑, *Dose↝, *Dose↝, *toxicity∅, *toxicity↓, *BP↓, *Inflam↓, *Bacteria↓, *Imm↑, *lipid-P↓, *AST↓, *ALAT↓, *AntiAg↑, *ROS↓, *AntiThr↑,
6353- DRE,  Cisplatin,    Insights Into Protective Mechanisms of Dandelion Leaf Extract Against Cisplatin-Induced Nephrotoxicity in Rats: Role of Inhibitory Effect on Inflammatory and Apoptotic Pathways
- in-vivo, Nor, NA
*antiOx↑, *Inflam↓, *Apoptosis↓, *NF-kB↓, *Cyt‑c↓, *DNAdam↓, *GSH↑, *SOD↑, *Albumin↝, *creat↓, *BUN↓, *RenoP↑, *lipid-P↓, *TNF-α↓, *Casp3↓, *Casp9↓, *chemoP↑,
6354- DRE,    Taraxacum officinale L. in leukemia and lymphoma: current knowledge and prospects for horticulture
- Review, AML, NA
ROS↑, mt-Apoptosis↑, TumCCA↑, PI3K↓, Akt↓, STAT3↓, Dose↝, *hepatoP↑, Casp8↑, mtDam↑, TumCD↑, selectivity↑, DNAdam↑, BAX↑, P53↑, Bcl-2↓, CSCs↓, *toxicity↓, tumCV↓, Imm↑, FAK↓, mTOR↓, ChemoSen↑, eff↝, eff↑,
6351- DRE,  Rad,    Differential effect of Taraxacum officinale L. (dandelion) root extract on hepatic and testicular tissues of rats exposed to ionizing radiation
- in-vivo, Nor, NA
*radioP↑, *ROS↓, *MDA↓, *GSH↑, *SOD↑, *IL1β↓, *TNF-α↓, *Casp3↓, *eff↑,
6352- DRE,    Investigation of the Anti-Lung Cancer Mechanisms of Taraxacum officinale Based on Network Pharmacology and Multidimensional Experimental Validation
- in-vitro, Lung, A549 - in-vitro, Nor, L929
other↝, other↝, tumCV↑, selectivity?, EGFR↓, AKT1↓, NQO1↓,
6365- DRE,    AN OVERVIEW OF THERAPEUTIC POTENTIALS OF TARAXACUM OFFICINALE (DANDELION): A TRADITIONALLY VALUABLE HERB WITH A REACH HISTORICAL BACKGROUND
- Review, Var, NA
*Inflam↓, *AntiTum↑, *Imm↑, *antiOx↑, *AntiDiabetic↑, *diuretic↑, *RenoP↑, *hepatoP↑, *neuroP↑, AntiTum↑, TNF-α↑, IL1β↑, Apoptosis↑, MMP2↓, MMP9↑, eff↑, Diff↑, *ROS↓, *HO-1↑, *NRF2↑, *lipid-P↓,
6358- DRE,    Dandelion root extracts and taraxasterol inhibit LPS‑induced colorectal cancer cell viability by blocking TLR4‑NFκB‑driven ACE2 and TMPRSS2 pathways
- in-vitro, CRC, NA
TLR4↓, NF-kB↓, TNF-α↓, IL4↓, IL6↓, tumCV↓,
6359- DRE,    Natural Health Products (NHP’s) and Natural Compounds as Therapeutic Agents for the Treatment of Cancer; Mechanisms of Anti-Cancer Activity of Natural Compounds and Overall Trends
- Review, Var, NA
*antiOx↑, *Inflam↓, Dose↝, PI3K↓, Akt↓, NF-kB↓,
6360- DRE,    Dandelion Seed Extract Affects Tumor Progression and Enhances the Sensitivity of Cisplatin in Esophageal Squamous Cell Carcinoma
- in-vitro, ESCC, KYSE450 - in-vitro, ESCC, Eca109
TumCG↓, TumCP↓, TumCMig↓, TumCI↓, angioG↓, Apoptosis↑, PI3K↓, Akt↓, p‑Akt↓, survivin↓, Bax:Bcl2↑, Casp3↑, Casp9↑, MMP2↓, MMP9↓, VEGF↓, EMT↓, eff↑, DNAdam↑, p‑STAT3↑, ChemoSen↑,
6367- DRE,    Antioxidant and antimicrobial activities of Dandelion root extract (Taraxacum officinale) and its cytotoxic effect on MDA-MB-231 breast cancer cells
- in-vitro, BC, MDA-MB-231
TumCD↑, *antiOx↑, *ROS↓, tumCV↓, Apoptosis↑, ROS↑, TumCCA↑, MOMP↑, ROS↑,
6361- DRE,    Taraxacum officinale Seed Extract Inhibits HeLa Cell Migration at Sub-cytotoxic Concentrations
- in-vitro, Cerv, HeLa
tumCV↓, TumCMig↓,
6362- DRE,    Taraxacum spp. in vitro and in vivo anticancer activity – A review
- Review, Var, NA
tumCV↓, *AntiDiabetic↑, *Imm↑,
6363- DRE,    Therapeutic Potential of Dandelion (Taraxacum officinale) Root Extract in Colon Cancer: A Comprehensive Review
- in-vitro, CRC, NA
Apoptosis↑, *Inflam↓, TLR4↓, NF-kB↓, *GutMicro↑, mtDam↑, *ROS↓, Casp1↑, TNF-α↑, Bcl-2↓, PARP↓, MMP↓, Cyt‑c↓, Casp3↑, TumVol↓, COX2/PTGS2↓, iNOS↓, ROS↑, selectivity↑, TumCMig↓, TumCI↓, ER Stress↑, PERK↑, eIF2α↑, ATF4↑, CHOP/DDIT3↑, TumCCA↑, cycD1/CCND1↓, P21↓, P53↑, BioAv↝, Half-Life↝,
6364- DRE,    Dandelion Root Extract Sensitizes Leukemia Cells to VP-16 Induced Cell Death
- in-vitro, CLL, NA
TumCP↓, MMP↓, ROS↑, TumCD↑, ChemoSen↑, chemoP↑, QoL↑,
6366- DRE,    A comprehensive review of the benefits of Taraxacum officinale on human health
- Review, Var, NA
*diuretic↑, *hepatoP↑, *Imm↑, *Bacteria↓, *AntiArt↑, *AntiDiabetic↑, *Obesity↓, *antiOx↓, *AntiCan↑, Dose?,
6738- DSF,    Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
- Review, Var, NA
eff↑, NPL4↓,
6743- DSF,    Disulfiram/Copper Activates ER Stress to Promote Immunogenic Cell Death of Oral Squamous Cell Carcinoma
- in-vitro, OS, NA
TumCG↓, Apoptosis↑, ER Stress↑,
6742- DSF,    Localized Sustained Release of Copper Enhances Anti-Tumor Effects of Disulfiram in Head and Neck Cancer
- in-vitro, HNSCC, NA
TumCG↓, NPL4↓,
6741- DSF,    Actionable cancer vulnerability due to translational arrest, p53 aggregation and ribosome biogenesis stress evoked by the disulfiram metabolite CuET
- vitro+vivo, Lung, A549
NPL4↓, P53↑,
6744- DSF,    Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, T47D
TumCD↑, ChemoSen↑, BAX↑, Apoptosis↑, CSCs↓, ROS↑, eff↝, JNK↑, p38↑, NF-kB↓,
6740- DSF,    Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway
NPL4↓, other↝, DNAdam↑,
6739- DSF,    Disulfiram's anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase
- in-vitro, Lung, H1299 - in-vitro, Lung, A549
ALDH↓, eff↝, NPL4↓,
4913- DSF,    Anticancer effects of disulfiram: a systematic review of in vitro, animal, and human studies
- Review, Var, NA
Apoptosis↑, tumCV↑, eff↑, toxicity↓, antiNeop↑, ChemoSen↑, RadioS↑, OS↑, ROS↑, SOD↓, MMP1↓, eff↑, Half-Life↓,
4914- DSF,  immuno,    Disulfiram and cancer immunotherapy: Advanced nano-delivery systems and potential therapeutic strategies
- Review, Var, NA
AntiTum↑, eff↑, ALDH↓, Dose↝, RadioS↑, angioG↓, TumMeta↓, BioAv↝, ROS↑, DNAdam↑, P-gp/ABCB1↓, CSCs↓, EMT↓, Imm↑, SOD↓, MAPK↓, NF-kB↓, ChemoSen↑, eff↑, toxicity↝, BioAv↑, *Inflam↓, Sepsis↓,
4916- DSF,  Cu,    The immunomodulatory function and antitumor effect of disulfiram: paving the way for novel cancer therapeutics
- Review, Var, NA
TumCP↓, TumCMig↓, TumCI↓, eff↑, Imm↑, ROS↑, NF-kB↓, chemoP↑, JNK↑, FOXO↑, Myc↑, TumCCA↑, Apoptosis↑, RadioS↑, PD-L1↑, eff↑, CSCs↓, Dose↝, Half-Life↑,
4917- DSF,  Chemo,  Cu,    Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma
- Trial, GBM, NA
OS∅, toxicity↑,
4915- DSF,  Cu,    Disulfiram: A novel repurposed drug for cancer therapy
- Review, Var, NA
ROS↑, TumCD↑, NF-kB↓, CSCs↓, ChemoSen↑, RadioS↑, eff↑, selectivity↑, Proteasome?,
5007- DSF,  Cu,    Nrf2/HO-1 Alleviates Disulfiram/Copper-Induced Ferroptosis in Oral Squamous Cell Carcinoma
- vitro+vivo, Oral, NA
AntiTum↑, TumCP↓, Ferroptosis↑, Iron↑, lipid-P↑, NRF2↓, HO-1↓,
5008- DSF,  Cu,    Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis
- in-vitro, HCC, NA
selectivity↑, TumCD↑, TumCMig↓, TumCI↓, angioG↓, mtDam↑, Iron↑, lipid-P↑, Ferroptosis↑, NF-kB↑, p‑p62↑, Keap1↓, eff↑, eff↓, ChemoSen↑,
5009- DSF,  Cu,    Activation of Oxidative Stress and Down-Regulation of Nuclear Factor Erythroid 2-Related Factor May Be Responsible for Disulfiram/Copper Complex Induced Apoptosis in Lymphoid Malignancy Cell Lines
- vitro+vivo, lymphoma, NA
AntiTum↑, ROS↑, JNK↑, NRF2↓, eff↓, TumCD↑,
5010- DSF,  Cu,  Rad,    Disulfiram/Copper Combined with Irradiation Induces Immunogenic Cell Death in Melanoma
- in-vivo, Melanoma, B16-F10
Apoptosis↑, ICD↑, HMGB1↑, ATP↓, TumCG↓,
5011- DSF,  Cu,    Leveraging disulfiram to treat cancer: Mechanisms of action, delivery strategies, and treatment regimens
- Review, Var, NA
BioAv↓, eff↓, ChemoSen↑, RadioS↑,
5012- DSF,  Cu,    Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems
ROS↑, ALDH↓, TumCP↓, CSCs↓, angioG↓, TumMeta↓, DNAdam↑, Proteasome↓, SOD1↓, GSR↓, ox-GSSG↑, GSH/GSSG↓, MMP↓, Akt↓, cycD1/CCND1↓, NF-kB↓, CSCs↓, MAPK↓, angioG↓, DrugR↓, EMT↓, Vim↓, BioAv↑, eff↑,
5006- DSF,  Cu,    Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition
- vitro+vivo, lymphoma, NA
TumCD↑, TumCP↑, Apoptosis↑, NRF2↓, ROS↑, p‑JNK↑, p65↓, eff↓, NF-kB↓,
5013- DSF,  Cu,  Z,    Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease
- vitro+vivo, Melanoma, NA - Case Report, Melanoma, NA
P-gp/ABCB1↓, NF-kB↓, ChemoSen↑, angioG↓, TumCG↓, TumMeta↓, Remission↑, toxicity↓, ATF2↓, CREB↓, cycA1/CCNA1↓, TumCG↓, angioG↓, Dose↝, toxicity↝,
4252- EA,    Effect of ellagic acid on BDNF/PI3K/AKT-mediated signaling pathways in mouse models of depression
- in-vivo, NA, NA
*BDNF↑, *p‑AKT1↑,
4253- EA,    The effects of Ellagic acid supplementation on neurotrophic, inflammation, and oxidative stress factors, and indoleamine 2, 3-dioxygenase gene expression in multiple sclerosis patients with mild to moderate depressive symptoms: A randomized, triple-blind, placebo-controlled trial
- Human, MS, NA - NA, IBD, NA
*Mood↑, *BDNF↑, *5HT↑, *antiOx↑, *Inflam↓, *AntiCan↑, *QoL↑, *neuroP↑, *cognitive↑, *memory↑, *Dose↝,
4254- EA,    Chronic administration of ellagic acid improved the cognition in middle-aged overweight men
- Human, Obesity, NA
*LDL↓, *HDL↑, *BDNF↑, *cognitive↑,
4255- EA,    Effects of nutritional interventions on BDNF concentrations in humans: a systematic review
- Review, NA, NA
*BDNF↑,
4832- EA,    Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid
*antiOx↑, *AntiCan↑, TumCMig↓, angioG↓, ChemoSen↑, RadioS↑, *chemoP↑, *BioAv↓, eff↓, selectivity↑, MMP2↓, MMP9↓, VEGF↓, TumCCA↑, Apoptosis↑, ROS↑, BioAv↑,
4341- EA,    Novel Bioactivity of Ellagic Acid in Inhibiting Human Platelet Activation
- in-vitro, NA, NA
*AntiAg↑, *AntiAg↑,
6806- EA,    Improving Effect of Ellagic Acid on Sleep Quality and Gastrointestinal Symptoms in Patient With Irritable Bowel Syndrome: Randomized Double-Blind Clinical Trial
- Human, IBD, NA
*Sleep↑, *antiOx↑, *Inflam↓,
6805- EA,    The gut microbiota urolithin metabotypes revisited: the human metabolism of ellagic acid is mainly determined by aging
- Human, Nor, NA
*other↝, other↝,
6804- EA,    Ellagic acid metabolism by human gut microbiota: consistent observation of three urolithin phenotypes in intervention trials, independent of food source, age, and health status
- Human, Nor, NA
*other?, *Risk↓, *GutMicro↝,
6803- EA,    Effects of Ellagic Acid on Oxidative Stress Index, Inflammatory Markers and Quality of Life in Patients With Irritable Bowel Syndrome: Randomized Double-blind Clinical Trial
- Trial, IBD, NA
*Dose↝, *MDA↓, *TAC↑, *CRP↓, *IL6↓, *Inflam↓, *ROS↓, *QoL↑, *toxicity↓,
6802- EA,    Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate
- Human, Pca, NA
*toxicity↓, chemoP↑, Neut↑, PSA↓, Dose↝,
6801- EA,    A radiotherapeutic paradox: ellagic acid sensitizes tumors while attenuating radiation-induced myocardial injury
- vitro+vivo, BC, 4T1
TumCCA↑, CDK4↓, RadioS↑, TumCG↓, *radioP↑, *cardioP↑, *antiOx↑, *ROS↓, Dose↑, selectivity↑, BioAv↓,
2402- EA,    Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase
- in-vitro, NA, NA
PKL↓,
1607- EA,    Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions
- Review, GC, NA
STAT3↓, TumCP↓, Apoptosis↑, NF-kB↓, EMT↓, RadioS↑, antiOx↑, COX1↓, COX2/PTGS2↓, cMyc↓, Snail↓, Twist↓, MMP2↓, P90RSK↓, CDK8↓, PI3K↓, Akt↓, TumCCA↑, Casp8↑, PCNA↓, TGF-β↓, Shh↓, NOTCH↓, IL6↓, ALAT↓, ALP↓, AST↓, VEGF↓, P21↑, *toxicity∅, *Inflam↓, *cardioP↑, *neuroP↑, *hepatoP↑, ROS↑, *NRF2↓, *GSH↑,
1605- EA,    Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence
- Review, Var, NA
*BioAv↓, antiOx↓, Inflam↓, TumCP↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, P53↑, P21↑, COX2/PTGS2↓, NF-kB↓, Akt↑, NOTCH↓, CDK2↓, CDK6↓, JAK↓, STAT3↓, EGFR↓, p‑ERK↓, p‑Akt↓, p‑STAT3↓, TGF-β↓, SMAD3↓, CDK6↓, Wnt/(β-catenin)↓, Myc↓, survivin↓, CDK8↓, PKCδ↓, tumCV↓, RadioS↑, eff↑, MDM2↓, XIAP↓, p‑RB1↓, PTEN↑, p‑FAK↓, Bax:Bcl2↑, Bcl-xL↓, Mcl-1↓, PUMA↑, NOXA↑, MMP↓, Cyt‑c↑, ROS↑, Ca+2↝, Endoglin↑, Diablo↑, AIF↑, iNOS↓, Casp9↑, Casp3↑, cl‑PARP↑, RadioS↑, Hif1a↓, HO-1↓, HO-2↓, SIRT1↓, selectivity↑, Dose∅, NHE1↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PDK1 / PDPK1?, PDK1 / PDPK1?, ECAR↝, COX1↓, Snail↓, Twist↓, cMyc↓, Telomerase↓, angioG↓, MMP2↓, MMP9↓, VEGF↓, Dose↝, PD-L1↓, eff↑, SIRT6↑, DNAdam↓,

Showing Research Papers: 3251 to 3300 of 8269
Prev Page 66 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8269

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NPL4↓, 5,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 1,   Ferroptosis↑, 2,   GSH/GSSG↓, 1,   GSR↓, 1,   ox-GSSG↑, 1,   HO-1↓, 2,   HO-2↓, 1,   ICD↑, 1,   Iron↑, 2,   Keap1↓, 1,   lipid-P↑, 2,   NQO1↓, 1,   NRF2↓, 3,   ROS↑, 16,   SOD↓, 2,   SOD1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   ATP↓, 1,   MMP↓, 4,   mtDam↑, 3,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AKT1↓, 1,   ALAT↓, 1,   cMyc↓, 2,   CREB↓, 1,   ECAR↝, 1,   GlucoseCon↓, 1,   Glycolysis↓, 1,   lactateProd↓, 1,   PDK1 / PDPK1?, 2,   PKL↓, 1,   SIRT1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 5,   Akt↑, 1,   p‑Akt↓, 2,   Apoptosis↑, 12,   mt-Apoptosis↑, 1,   ATF2↓, 1,   BAX↑, 2,   Bax:Bcl2↑, 2,   Bcl-2↓, 2,   Bcl-xL↓, 1,   Casp1↑, 1,   Casp3↑, 3,   Casp8↑, 2,   Casp9↑, 2,   Cyt‑c↓, 1,   Cyt‑c↑, 1,   Diablo↑, 1,   Ferroptosis↑, 2,   iNOS↓, 2,   JNK↑, 3,   p‑JNK↑, 1,   MAPK↓, 2,   Mcl-1↓, 1,   MDM2↓, 1,   MOMP↑, 1,   Myc↓, 1,   Myc↑, 1,   NOXA↑, 1,   p38↑, 1,   Proteasome?, 1,   Proteasome↓, 1,   PUMA↑, 1,   survivin↓, 2,   Telomerase↓, 1,   TumCD↑, 8,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 4,   tumCV↓, 6,   tumCV↑, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   eIF2α↑, 1,   ER Stress↑, 2,   PERK↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

p‑p62↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,   DNAdam↑, 5,   P53↑, 4,   PARP↓, 1,   cl‑PARP↑, 1,   PCNA↓, 1,   SIRT6↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 1,   cycA1/CCNA1↓, 1,   cycD1/CCND1↓, 3,   cycE/CCNE↓, 1,   P21↓, 1,   P21↑, 2,   p‑RB1↓, 1,   TumCCA↑, 8,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 3,   CDK8↓, 2,   CSCs↓, 7,   Diff↑, 1,   EMT↓, 4,   p‑ERK↓, 1,   FOXO↑, 1,   mTOR↓, 1,   NOTCH↓, 2,   P90RSK↓, 1,   PI3K↓, 4,   PTEN↑, 1,   Shh↓, 1,   STAT3↓, 3,   p‑STAT3↓, 1,   p‑STAT3↑, 1,   TumCG↓, 7,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↝, 1,   FAK↓, 1,   p‑FAK↓, 1,   MMP1↓, 1,   MMP2↓, 5,   MMP9↓, 3,   MMP9↑, 1,   PKCδ↓, 1,   SMAD3↓, 1,   Snail↓, 2,   TGF-β↓, 2,   TumCI↓, 4,   TumCMig↓, 6,   TumCP↓, 7,   TumCP↑, 1,   TumMeta↓, 3,   Twist↓, 2,   Vim↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 9,   ATF4↑, 1,   EGFR↓, 2,   Endoglin↑, 1,   Hif1a↓, 1,   VEGF↓, 4,  

Barriers & Transport(tgid=15) ⓘ

NHE1↓, 1,   P-gp/ABCB1↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX1↓, 2,   COX2/PTGS2↓, 3,   HMGB1↑, 1,   IL1β↑, 1,   IL4↓, 1,   IL6↓, 2,   Imm↑, 3,   Inflam↓, 1,   JAK↓, 1,   Neut↑, 1,   NF-kB↓, 12,   NF-kB↑, 1,   p65↓, 1,   PD-L1↓, 1,   PD-L1↑, 1,   PSA↓, 1,   TLR4↓, 2,   TNF-α↓, 1,   TNF-α↑, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 3,   BioAv↝, 2,   ChemoSen↑, 11,   Dose?, 1,   Dose↑, 1,   Dose↝, 7,   Dose∅, 1,   DrugR↓, 1,   eff↓, 5,   eff↑, 15,   eff↝, 3,   Half-Life↓, 1,   Half-Life↑, 1,   Half-Life↝, 1,   RadioS↑, 10,   selectivity?, 1,   selectivity↑, 7,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   ALP↓, 1,   AST↓, 1,   EGFR↓, 2,   IL6↓, 2,   Myc↓, 1,   Myc↑, 1,   PD-L1↓, 1,   PD-L1↑, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

antiNeop↑, 1,   AntiTum↑, 4,   chemoP↑, 3,   OS↑, 1,   OS∅, 1,   QoL↑, 1,   Remission↑, 1,   toxicity↓, 2,   toxicity↑, 1,   toxicity↝, 2,   TumVol↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

Sepsis↓, 1,  
Total Targets: 197

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiArt↑, 1,   diuretic↑, 2,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 8,   GSH↑, 3,   HDL↑, 1,   HO-1↑, 1,   lipid-P↓, 3,   MDA↓, 2,   NRF2↓, 1,   NRF2↑, 1,   ROS↓, 7,   SOD↑, 2,   TAC↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

p‑AKT1↑, 1,   ALAT↓, 1,   BUN↓, 1,   LDL↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,   Casp3↓, 2,   Casp9↓, 1,   Cyt‑c↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 1,   other?, 1,   other↝, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 3,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CRP↓, 1,   IL1β↓, 1,   IL6↓, 1,   Imm↑, 4,   Inflam↓, 10,   NF-kB↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↑, 1,   BDNF↑, 4,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   Dose↝, 4,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   Albumin↝, 1,   AST↓, 1,   BP↓, 1,   creat↓, 1,   CRP↓, 1,   GutMicro↑, 1,   GutMicro↝, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 3,   AntiDiabetic↑, 3,   AntiTum↑, 1,   cardioP↑, 3,   chemoP↑, 2,   cognitive↑, 2,   hepatoP↑, 4,   memory↑, 1,   Mood↑, 1,   neuroP↑, 3,   Obesity↓, 1,   QoL↑, 2,   radioP↑, 2,   RenoP↑, 2,   Risk↓, 1,   Sleep↑, 1,   toxicity↓, 4,   toxicity∅, 2,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 2,  
Total Targets: 67

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page